452
These results support the potential for antiparkinsonian clinical use of a combined treatment consisting in l - DOPA and a mGlu4 receptor PAM to reduce efficacious l - DOPA doses ( generally known as l - DOPA sparing ) , while maintaining the same benefit on PD motor troubles , and at the same time minimizing the development of LID .
 Chemical: l - DOPA; Chemical: l - DOPA; Chemical: l - DOPA
Please list all entity words in the text that fit the category.Output format is "type1: word1; type2: word2". 
Option: Chemical 
Text: {0} 
Answer:
 Chemical: l - DOPA; Chemical: l - DOPA; Chemical: l - DOPA